Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 10:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Long Term Follow-Up Clear all
Enrolling by invitation No phase listed Observational

A Long-Term Follow-Up Study of Participants With Cystinosis Who Previously Received CTNS-RD-04

NCT05146830
View directory record Official record
Conditions
Cystinosis
Interventions
Safety and Efficacy Assessments
Other
Lead sponsor
Stephanie Cherqui
Other
Eligibility
14 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2036
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Jun 25, 2026, 10:49 PM EDT
Active, not recruiting Phase 1 Interventional

Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC)

NCT06155500
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
OTQ923
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2039
U.S. locations
3
States / cities
Chicago, Illinois • New York, New York • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Jun 25, 2026, 10:49 PM EDT
Terminated No phase listed Observational

Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product

NCT03436771
View directory record Official record
Conditions
Non Hodgkin Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
Interventions
JCAR017, JCARH125
Genetic
Lead sponsor
Juno Therapeutics, a Subsidiary of Celgene
Industry
Eligibility
Not listed
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
2
States / cities
Duarte, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 3, 2020 · Synced Jun 25, 2026, 10:49 PM EDT
Terminated Phase 2 Interventional Results available

Open-label Study to Assess the Safety and Efficacy of CDP6038 (Olokizumab) in Patients Who Completed RA0056

NCT01296711
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CDP6038 (olokizumab)
Biological
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
50
States / cities
Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Jun 25, 2026, 10:49 PM EDT
Active, not recruiting No phase listed Observational

The Long-Term EVAR Assessment and Follow-Up (LEAF) Study for the AFX2 System

NCT06990048
View directory record Official record
Conditions
Abdominal Aortic Aneurysm
Interventions
AFX2 System
Device
Lead sponsor
Endologix
Industry
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jun 25, 2026, 10:49 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Evaluation of the Long Term Follow up of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

NCT03920215
View directory record Official record
Conditions
Long Term Follow up Dry Eye Disease
Interventions
OC-01 Low Dose, 0.12 mg/mL, OC-01 Mid Dose, 0.6 mg/mL, OC-01 High Dose, 1.2 mg/mL, Placebo (vehicle) nasal spray
Drug
Lead sponsor
Oyster Point Pharma, Inc.
Industry
Eligibility
22 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Newport Beach, California • Indianapolis, Indiana • Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Jun 25, 2026, 10:49 PM EDT
Recruiting No phase listed Observational

Long Term Follow-Up Study for Individuals With Hemoglobin Disorders After Hematopoietic Cell Transplant or Gene Therapy

NCT06646640
View directory record Official record
Conditions
Hemoglobin Disorder
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2050
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Jun 25, 2026, 10:49 PM EDT
Enrolling by invitation No phase listed Observational

Long Term Follow-up Study for Subjects Administered CLBR001

NCT06882317
View directory record Official record
Conditions
Long Term Follow-Up
Interventions
Long Term Follow-Up
Other
Lead sponsor
Calibr, a division of Scripps Research
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2044
U.S. locations
3
States / cities
Indianapolis, Indiana • Morrisville, North Carolina • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Jun 25, 2026, 10:49 PM EDT
Recruiting Phase 4 Interventional

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

NCT05803941
View directory record Official record
Conditions
Prostate Cancer
Interventions
AAA617
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
24
States / cities
Scottsdale, Arizona • Orange, California • Santa Monica, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jun 25, 2026, 10:49 PM EDT
Completed No phase listed Observational Results available

Trifecta™ Long Term Follow-Up (LTFU) Study

NCT01593917
View directory record Official record
Conditions
Aortic Valve Insufficiency, Aortic Valve Regurgitation, Aortic Valve Stenosis, Aortic Valve Incompetence
Interventions
Trifecta™ Valve
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
9
States / cities
Los Angeles, California • Minneapolis, Minnesota • Rochester, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Jun 25, 2026, 10:49 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study for Long-term Follow-up of Hemophagocytic Lymphohistiocytosis (HLH) Participants Who Received Treatment With Emapalumab (NI-0501), an Anti-interferon Gamma Monoclonal Antibody

NCT02069899
View directory record Official record
Conditions
Hemophagocytic Lymphohistiocytosis
Interventions
Emapalumab
Drug
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
Not listed
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
5
States / cities
Grand Rapids, Michigan • Chapel Hill, North Carolina • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2022 · Synced Jun 25, 2026, 10:49 PM EDT
Recruiting No phase listed Observational

A Safety and Efficacy Long-Term Follow-up Study of Adult Participants Treated With Gene Modified T Cells

NCT06798298
View directory record Official record
Conditions
Long Term Safety Following GM T Cell Therapy
Interventions
Non-interventional
Genetic
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2040
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 23, 2025 · Synced Jun 25, 2026, 10:49 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine

NCT00359619
View directory record Official record
Conditions
Infections, Papillomavirus, Papillomavirus Vaccines
Interventions
CervarixTM, HPV investigational vaccine GSK568893A, different formulations
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 25 Years · Female only
Enrollment
383 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
4
States / cities
Denver, Colorado • Golden, Colorado • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 1, 2020 · Synced Jun 25, 2026, 10:49 PM EDT
Completed No phase listed Observational

Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs

NCT05292859
View directory record Official record
Conditions
Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer, Non-small Cell Lung Cancer, Cholangiocarcinoma, Ovarian Cancer, Ovary Neoplasm, Squamous Cell Lung Cancer, Adenocarcinoma of Lung, Adenosquamous Cell Lung Cancer
Interventions
Neoantigen specific TCR-T cell drug product
Biological
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Jun 25, 2026, 10:49 PM EDT
Completed Phase 3 Interventional Results available

Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease

NCT00333788
View directory record Official record
Conditions
Crohn's Disease
Interventions
Certolizumab pegol (CDP870)
Biological
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
19
States / cities
Gainesville, Florida • Atlanta, Georgia • Chicago, Illinois + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Jun 25, 2026, 10:49 PM EDT
Not yet recruiting No phase listed Observational

Understanding the Long-term Impact of COVID-19 in Adults

NCT07498504
View directory record Official record
Conditions
Long COVID, Long Covid19
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Enrollment
5,205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jun 25, 2026, 10:49 PM EDT
Enrolling by invitation No phase listed Observational

Long Term Follow up of the LTOG Cohort

NCT04787822
View directory record Official record
Conditions
Lung Transplant Failure and Rejection
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
13 Years and older
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
10
States / cities
Birmingham, Alabama • San Francisco, California • Stanford, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jun 25, 2026, 10:49 PM EDT
Recruiting No phase listed Observational

A Long-Term Follow-Up Study of Participants Exposed to REACT

NCT05918523
View directory record Official record
Conditions
Diabetic Kidney Disease, Chronic Kidney Diseases
Interventions
Renal Autologous Cell Therapy (REACT)
Biological
Lead sponsor
Prokidney
Industry
Eligibility
30 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Meridian, Idaho
Source: ClinicalTrials.gov public record
Updated May 27, 2025 · Synced Jun 25, 2026, 10:49 PM EDT
Active, not recruiting Not applicable Interventional

Post Market Clinical Follow-up (PMCF) Study of Clareon Vivity & Clareon PanOptix

NCT05796453
View directory record Official record
Conditions
Aphakia, Astigmatism, Presbyopia
Interventions
Clareon Vivity IOL - Non Toric, Clareon Vivity IOL - Toric, Clareon PanOptix Trifocal IOL - Non Toric, Clareon PanOptix Trifocal IOL - Toric
Device
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
6
States / cities
Torrance, California • Jacksonville, Florida • Liverpool, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Jun 25, 2026, 10:49 PM EDT
Terminated No phase listed Observational

Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy

NCT04093622
View directory record Official record
Conditions
Hematological Malignancy
Interventions
Genetically engineered NK cells
Genetic
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
Phoenix, Arizona • San Diego, California • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2022 · Synced Jun 25, 2026, 10:49 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Donors With Nephrolithiasis at the Time of Transplant Evaluation (DONATE). Long Term Follow-up.

NCT05519150
View directory record Official record
Conditions
Kidney Stones
Interventions
low dose radiation abdomen/pelvis CT scan (stone protocol), Blood draw, 24 hour urine collection
Diagnostic Test · Procedure · Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Jun 25, 2026, 10:49 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Long Term Follow Up to Determine the Effects of Collagenase SANTYL Ointment on Scar Formation

NCT01705860
View directory record Official record
Conditions
Follow up to Acute Wound Scar Study
Interventions
Santyl
Biological
Lead sponsor
Healthpoint
Industry
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2013 · Synced Jun 25, 2026, 10:49 PM EDT
Terminated No phase listed Observational

Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product

NCT02840110
View directory record Official record
Conditions
B Cell Lymphomas, Multiple Myeloma, Solid Tumor, HER-2 Protein Overexpression
Interventions
ACTR T Cell Product
Other
Lead sponsor
Cogent Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
16
States / cities
Gilbert, Arizona • Phoenix, Arizona • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2021 · Synced Jun 25, 2026, 10:49 PM EDT
Terminated No phase listed Observational

Registry Measuring the Impact of Adding RNA Expression Testing on Referral Decisions in Early Stage Lung Cancer Patients and Assessing the Disease-free Survival With Long-term Follow-up

NCT02121925
View directory record Official record
Conditions
Lung Cancer, NSCLC, Lung Adenocarcinoma
Interventions
Not listed
Lead sponsor
Myriad Genetic Laboratories, Inc.
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 4, 2017 · Synced Jun 25, 2026, 10:49 PM EDT